Catalysts / TRVI
Upcoming FDA decisions and readouts we track for Trevi Therapeutics, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for Trevi Therapeutics (TRVI, listed on Nasdaq). All of them concern Haduvio (nalbuphine ER) (Chronic cough in idiopathic pulmonary fibrosis; Refractory chronic cough; Chronic cough in IPF — 52-week fixed dosing).
First on the list: the Phase 3 readout for Haduvio (nalbuphine ER) (Chronic cough in idiopathic pulmonary fibrosis), guided by the company to H2 2027. The furthest-out event tracked is H1 2028. By stage, the upcoming rows are 1 Phase 2B readout and 2 Phase 3 readouts.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: How to read a Phase 3 topline readout; Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Trevi Therapeutics TRVI · Nasdaq | Haduvio (nalbuphine ER) | Chronic cough in idiopathic pulmonary fibrosis | H2 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Trevi Therapeutics TRVI · Nasdaq | Haduvio (nalbuphine ER) | Refractory chronic cough | H2 2027 company guidance |
Phase 2B readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Trevi Therapeutics TRVI · Nasdaq | Haduvio (nalbuphine ER) | Chronic cough in IPF — 52-week fixed dosing | H1 2028 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList